Report cover image

Post-Surgical Infection Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147022

Description

A post-surgical infection, also known as a surgical site infection (SSI), refers to infections after a surgical procedure. Such infections can result in poor wound healing and pain and might require further treatment. A post-surgical infection often occurs within 30 days after a surgical procedure. Studies show that the chances of developing such an infection post-surgery are around 1 to 3%. The growth in the volume of surgical procedures, especially among older adults, coupled with the rising focus on infection control protocols is anticipated to aid in the drug pipeline expansion.

Report Coverage

The Post-Surgical Infection Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into post-surgical infection drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for post-surgical infection. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The post-surgical infection pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from post-surgical infection.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to post-surgical infection.

Post-Surgical Infection Drug Pipeline Outlook

A post-surgical infection can cause fever, tenderness, redness, delayed healing, or swelling, among others. There are three types of post-surgical infections: superficial incisional SSI, deep incisional SSI, and organ or space SSI. These infections are commonly caused by the bacteria Streptococcus, Staphylococcus , and Pseudomonas . Age, diabetes, obesity, and smoking are some of the risk factors for developing a post-surgical infection.

Novel antibiotics and alternative therapies, such as antimicrobial peptides and bacteriophage treatments are increasingly being explored to combat resistant pathogens that cause post-surgical infections. Moreover, the rise in multidrug-resistant cases is shifting the focus towards phage therapy and CRISPR-modified bacteriophages to effectively target these bacterial strains.

Post-Surgical Infection – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of post-surgical infection drugs based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Peptides
  • Polymers
  • Biologics
By Route of Administration
  • Oral
  • Parenteral
  • Others
Post-Surgical Infection – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials for post-surgical infection.

Post-Surgical Infection – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the post-surgical infection pipeline analysis include small molecules, peptides, polymers, and biologics. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post-surgical infection.

Post-Surgical Infection Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the post-surgical infection drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in post-surgical infection clinical trials:
  • MinaPharm Pharmaceuticals
  • Aesculap AG
  • PolyPid Ltd.
  • Oticara Australia PTY LTD
  • GeneOne Life Science, Inc.
Post-Surgical Infection – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Oral Ciprodiazole®

Sponsored by MinaPharm Pharmaceuticals, the objective of the clinical trial is to evaluate the efficacy and safety of oral Ciprodiazole® in comparison to ciprofloxacin tablets and metronidazole tablets in pelvi-abdominal infections and after IV antibiotics in post-operative duration. The study is under Phase IV clinical development and has an estimated 312 participants.

Drug: povidone-iodine topical ointment

This Phase IV clinical study is aimed at evaluating intranasal povidone iodine (PVI) to prevent Staphylococcus aureus surgical site infections following orthopedic fixation procedures for high-energy lower extremity fractures. The interventional study has enrolled about 2000 subjects and is expected to be completed by February 2026.

Reasons To Buy This Report

The Post-Surgical Infection Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for post-surgical infection. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within post-surgical infection pipeline insights.

Key Questions Answered in the Post-Surgical Infection – Pipeline Insight Report
  • What is the current landscape of post-surgical infection pipeline drugs?
  • How many companies are developing post-surgical infection drugs?
  • How many phase III and phase IV drugs are currently present in post-surgical infection pipeline drugs?
  • Which companies/institutions are leading the post-surgical infection drug development?
  • What is the efficacy and safety profile of post-surgical infection pipeline drugs?
  • What are the opportunities and challenges present in the post-surgical infection drug pipeline landscape?
  • Which company is conducting major trials for post-surgical infection drugs?
  • What geographies are covered for post-surgical infection clinical trials?
  • What are emerging trends in post-surgical infection clinical trials?
Related Reports

Global Wound Care Market

Global Acute Bacterial Skin and Skin Structure Infections Treatment Market

Global Advanced Wound Care Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Post-Surgical Infection
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Post-Surgical Infection
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Post-Surgical Infection
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Post-Surgical Infection: Epidemiology Snapshot
5.1 Post-Surgical Infection Incidence by Key Markets
5.2 Post-Surgical Infection – Patients Seeking Treatment in Key Markets
6 Post-Surgical Infection: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Post-Surgical Infection: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Post-Surgical Infection, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Post-Surgical Infection Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Post-Surgical Infection Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Ciprodiazole, Drug: Ciprofloxacin Tablets & Metronidazole tablets
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: povidone-iodine topical ointment
10.2.3 Other Drugs
11 Post-Surgical Infection Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Vancomycin
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: Cefuroxime
11.2.3 Other Drugs
12 Post-Surgical Infection Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Post-Surgical Infection Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Post-Surgical Infection, Key Drug Pipeline Companies
14.1 MinaPharm Pharmaceuticals
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Aesculap AG
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 PolyPid Ltd.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Oticara Australia PTY LTD
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 GeneOne Life Science, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us